Next Article in Journal
Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer
Previous Article in Journal
Approach to Biomarker Testing: Perspectives from Various Specialties
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists

by 1, 1,2, 3,4 and 1,2,*
1
Department of Oncology, McMaster University, Hamilton, ON, Canada
2
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada
3
Department of Oncology, University of Edmonton, Edmonton, AB, Canada
4
Cross Cancer Institute at Alberta Health Services, Edmonton, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(3), 184-195; https://doi.org/10.3747/co.23.3023
Received: 8 March 2016 / Revised: 6 April 2016 / Accepted: 5 May 2016 / Published: 1 June 2016
Background: The management of small-cell lung cancer (SCLC) with radiotherapy (RT) varies, with many treatment regimens having been described in the literature. We created a survey to assess patterns of practice and clinical decision-making in the management of SCLC by Canadian radiation oncologists (ROS). Methods: A 35-item survey was sent by e-mail to Canadian ROS. The questions investigated the role of RT, the dose and timing of RT, target delineation, and use of prophylactic cranial irradiation (PCI) in limited-stage (LS) and extensive-stage (ES) SCLC. Results: Responses were received from 52 eligible ROS. For LS-SCLC, staging (98%) and simulation or dosimetric (96%) computed tomography imaging were key determinants of RT suitability. The most common dose and fractionation schedule was 40–45 Gy in 15 once-daily fractions (40%), with elective nodal irradiation performed by 31% of ROS. Preferred management of clinical T1/2aN0 SCLC favoured primary chemoradiotherapy (64%). For ES-SCLC, consolidative thoracic RT was frequently offered (88%), with a preferred dose and fractionation schedule of 30 Gy in 10 once-daily fractions (70%). Extrathoracic consolidative RT would not be offered by 23 ROS (44%). Prophylactic cranial irradiation was generally offered in LS-SCLC (100%) and ES-SCLC (98%) after response to initial treatment. Performance status, baseline cognition, and pre-PCI brain imaging were important patient factors assessed before an offer of PCI. Conclusions: Canadian ROS show practice variation in SCLC management. Future clinical trials and national treatment guidelines might reduce variability in the treatment of early-stage disease, optimization of dose and targeting in LS-SCLC, and definition of suitability for PCI or consolidative RT.
Keywords: small-cell lung cancer; radiotherapy; radiation; SCLC small-cell lung cancer; radiotherapy; radiation; SCLC
MDPI and ACS Style

Shahi, J.; Wright, J.R.; Gabos, Z.; Swaminath, A. Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists. Curr. Oncol. 2016, 23, 184-195. https://doi.org/10.3747/co.23.3023

AMA Style

Shahi J, Wright JR, Gabos Z, Swaminath A. Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists. Current Oncology. 2016; 23(3):184-195. https://doi.org/10.3747/co.23.3023

Chicago/Turabian Style

Shahi, J.; Wright, J.R.; Gabos, Z.; Swaminath, A. 2016. "Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists" Curr. Oncol. 23, no. 3: 184-195. https://doi.org/10.3747/co.23.3023

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop